AFT Pharmaceuticals targets NZ$300M revenue following growth
- AFT Pharmaceuticals reported sustained double-digit revenue growth across all divisions for the first half of FY27.
- The company reaffirmed its full-year operating profit guidance of NZ$28 million to NZ$32 million.
- Growth is driven by global expansion, including out-licensing Maxigesic IV in Japan and the Philippines and new US distribution.
AFT Pharmaceuticals (ASX:AFP) announced sustained double-digit revenue growth for the first half of FY27 while maintaining its full-year revenue target of NZ$300 million.
The business backed up its revenue goal by affirming its full-year operating profit guidance of NZ$28 million to NZ$32 million.
“For longer term growth, significant resources and focus continue to be directed towards our R&D pipeline in addition to ongoing new product in-licensing and market development, including new product launches in AFT affiliates,” said AFT Pharmaceuticals Managing Director Dr Hartley Atkinson.
The group secured its third US FDA approval for patented product Scomara and launched Maxigesic Rapid in the US alongside Mark Cuban’s Cost Plus Drugs Company.
Further validation came after R&D partner StablePharma published clinical trial data for its fridge-free vaccine technology in the medical journal The Lancet.
Following the announcement, the AFT Pharmaceuticals share price was unchanged at $3.50.
The New Zealand-based company develops, licenses, and distributes a portfolio of patented pharmaceutical products across global markets.
Its strategy relies on expanding its international hubs while progressing proprietary iron injectable treatments and fridge-free medicine research through clinical trials.
